BRPI0513486A - derivados de cicloamino 1,3 substituìdo e seu emprego como antagonistas de receptor de histamina-3 - Google Patents
derivados de cicloamino 1,3 substituìdo e seu emprego como antagonistas de receptor de histamina-3Info
- Publication number
- BRPI0513486A BRPI0513486A BRPI0513486-2A BRPI0513486A BRPI0513486A BR PI0513486 A BRPI0513486 A BR PI0513486A BR PI0513486 A BRPI0513486 A BR PI0513486A BR PI0513486 A BRPI0513486 A BR PI0513486A
- Authority
- BR
- Brazil
- Prior art keywords
- formula
- disorder
- compound
- disorders
- congestion
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
DERIVADOS DE CICLOAMINO 1,3 SUBSTITUìDO E SEU EMPREGO COMO ANTAGONISTAS DE RECEPTOR DE HISTAMINA-3. A presente invenção refere-se a compostos da fórmula I como definidos aqui, ou um sal farmaceuticamente aceitável dos mesmos; uma composição farmacêutica contendo um composto da fórmula I, um método de tratamento de um distúrbio ou condição que pode ser tratado antagonizando-se os receptores de histamina H3, o método compreendendo administrar a um mamífero em necessidade de tal tratamento um composto da fórmula I como descrito acima, e um método de tratamento de um distúrbio ou condição selecionado do grupo consistindo em depressão, distúrbios de humor, esquizofrenia, distúrbios de ansiedade, doença de Alzheimer, distúrbio de déficit de atenção (ADD), distúrbio de hiperatividade de déficit de atenção (ADHD), distúrbios psicóticos, distúrbios do sono, obesidade, vertigem, epilepsia, doença de movimento, doenças respiratórias, alergia, respostas alérgicas de vias aéreas induzidas por alergia, rinite alérgica, congestão nasal, congestão alérgica, congestão, hipotensão, doença cardiovascular, doenças do trato GI, hiper e hipo motilidade e secreção acídica do trato gastrointestinal, o método compreendendo administrar a um mamífero em necessidade de tal tratamento um composto da fórmula I como acima descrito.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58895404P | 2004-07-19 | 2004-07-19 | |
PCT/IB2005/002185 WO2006011042A1 (en) | 2004-07-19 | 2005-07-07 | 1, 3 substituted cycloamino derivatives and their use as histamine-3 receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0513486A true BRPI0513486A (pt) | 2008-05-06 |
Family
ID=35063136
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0513486-2A BRPI0513486A (pt) | 2004-07-19 | 2005-07-07 | derivados de cicloamino 1,3 substituìdo e seu emprego como antagonistas de receptor de histamina-3 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20060014733A1 (pt) |
EP (1) | EP1771438A1 (pt) |
JP (1) | JP2008506765A (pt) |
BR (1) | BRPI0513486A (pt) |
CA (1) | CA2574361A1 (pt) |
MX (1) | MXPA06014919A (pt) |
WO (1) | WO2006011042A1 (pt) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050245543A1 (en) * | 2004-04-30 | 2005-11-03 | Pfizer Inc | Histamine-3 receptor antagonists |
GT200600042A (es) * | 2005-02-10 | 2006-09-27 | Aventis Pharma Inc | Compuestos de bis arilo y heteroarilo sustituido como antagonistas selectivos de 5ht2a |
WO2006089076A2 (en) | 2005-02-18 | 2006-08-24 | Neurogen Corporation | Thiazole amides, imidazole amides and related analogues |
CN101263112B (zh) * | 2005-07-01 | 2012-10-10 | 伊莱利利公司 | 组胺h3受体药物、其制备和治疗用途 |
AU2007227681A1 (en) * | 2006-03-15 | 2007-09-27 | Wyeth | N-substituted-azacyclylamines as histamine-3 antagonists |
CN101432261A (zh) * | 2006-05-19 | 2009-05-13 | 惠氏公司 | 作为组织胺-3拮抗剂的n-苯甲酰基-吡咯烷-3-基胺和n-苄基-吡咯烷-3-基胺 |
CN101522614B (zh) | 2006-08-09 | 2014-06-25 | 史密丝克莱恩比彻姆公司 | 作为阿片样物质受体的拮抗剂或反向激动剂的化合物 |
DE602007009284D1 (de) * | 2006-09-29 | 2010-10-28 | Actelion Pharmaceuticals Ltd | 3-aza-bicycloä3.1.0ühexanderivate |
PE20081152A1 (es) * | 2006-10-06 | 2008-08-10 | Wyeth Corp | Azaciclilaminas n-sustituidas como antagonistas de histamina-3 |
ATE496043T1 (de) | 2006-12-01 | 2011-02-15 | Actelion Pharmaceuticals Ltd | 3-heteroaryl (amino bzw. amido)-1- (biphenyl bzw. phenylthiazolyl) carbonylpiperdinderivate als orexinrezeptor-inhibitoren |
AR064561A1 (es) * | 2006-12-28 | 2009-04-08 | Actelion Pharmaceuticals Ltd | Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina. |
CN1985993B (zh) * | 2006-12-29 | 2012-04-04 | 安徽辉克药业有限公司 | 增强记忆力的复方制剂 |
CL2008000836A1 (es) | 2007-03-26 | 2008-11-07 | Actelion Pharmaceuticals Ltd | Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras. |
CL2008001503A1 (es) * | 2007-05-24 | 2008-07-04 | Wyeth Corp | Compuestos derivados de azaciclilbenzamidas, antagonistas de histamina-3; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para tratar un trastorno neurodegenerativo, como alzheimer, parkinso |
AR067549A1 (es) * | 2007-07-16 | 2009-10-14 | Wyeth Corp | Compuesto de oxazol,tiazol e imidazol, composicion farmaceutica que lo comprende , proceso para la preparacion del compuesto , uso del compuesto y metodos para la inhibicion del receptor h3 y para el tratamiento de un trastorno cognitivo relacionado con o afectado por el receptor de histamina -3 (h3 |
AR067665A1 (es) | 2007-07-27 | 2009-10-21 | Actelion Pharmaceuticals Ltd | Derivados de trans-3- aza-biciclo ( 3.1.0) hexano |
NZ583487A (en) | 2007-07-27 | 2011-09-30 | Actelion Pharmaceuticals Ltd | 2-aza-bicyclo[3.3.0]octane derivatives |
EP2200989A1 (en) * | 2007-09-12 | 2010-06-30 | Wyeth a Corporation of the State of Delaware | Isoquinolinyl and isoindolinyl derivatives as histamine-3 antagonists |
TW200918062A (en) * | 2007-09-12 | 2009-05-01 | Wyeth Corp | Azacyclylisoquinolinone and-isoindolinone derivatives as histamine-3 antagonists |
WO2009040730A2 (en) * | 2007-09-24 | 2009-04-02 | Actelion Pharmaceuticals Ltd | Pyrrolidines and piperidines as orexin receptor antagonists |
CA2702320A1 (en) * | 2007-10-30 | 2009-05-07 | Arena Pharmaceuticals, Inc. | Biphenyl derivatives as modulators of the histamine-h3 receptor useful for the treatment of disorders related thereto |
RU2010138640A (ru) | 2008-02-21 | 2012-03-27 | Актелион Фармасьютиклз Лтд (Ch) | Производные 2-аза-бицикло [2.2.1] гептана |
BRPI1008060A2 (pt) * | 2009-02-10 | 2015-08-25 | Abbott Lab | Agonistas e antagonistas do receptor s1p5, e métodos de uso do mesmo. |
JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神分裂病を処置するための方法および組成物 |
CN105263914B (zh) * | 2013-01-09 | 2017-10-27 | 艾尼纳制药公司 | 联苯基‑乙基‑吡咯烷衍生物作为组胺h3受体调节剂用于治疗认知障碍 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6620839B2 (en) * | 2000-07-13 | 2003-09-16 | Abbott Laboratories | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications |
EP1379493A2 (en) * | 2001-03-23 | 2004-01-14 | Eli Lilly and Company | Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses |
JP2006512404A (ja) * | 2002-10-22 | 2006-04-13 | グラクソ グループ リミテッド | H3受容体リガンドとしてのアリールオキシアルキルアミン誘導体 |
US20050245543A1 (en) * | 2004-04-30 | 2005-11-03 | Pfizer Inc | Histamine-3 receptor antagonists |
EP1771449A1 (en) * | 2004-07-21 | 2007-04-11 | Pfizer Products Incorporated | Histamine-3 receptor antagonists |
-
2005
- 2005-06-16 US US11/155,085 patent/US20060014733A1/en not_active Abandoned
- 2005-07-07 JP JP2007522059A patent/JP2008506765A/ja active Pending
- 2005-07-07 WO PCT/IB2005/002185 patent/WO2006011042A1/en not_active Application Discontinuation
- 2005-07-07 EP EP05759129A patent/EP1771438A1/en not_active Withdrawn
- 2005-07-07 BR BRPI0513486-2A patent/BRPI0513486A/pt not_active Application Discontinuation
- 2005-07-07 CA CA002574361A patent/CA2574361A1/en not_active Abandoned
- 2005-07-07 MX MXPA06014919A patent/MXPA06014919A/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP1771438A1 (en) | 2007-04-11 |
US20060014733A1 (en) | 2006-01-19 |
MXPA06014919A (es) | 2007-02-28 |
CA2574361A1 (en) | 2006-02-02 |
JP2008506765A (ja) | 2008-03-06 |
WO2006011042A1 (en) | 2006-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0513486A (pt) | derivados de cicloamino 1,3 substituìdo e seu emprego como antagonistas de receptor de histamina-3 | |
BRPI0507374A (pt) | moduladores do receptor de histamina-3 | |
BRPI0513444A (pt) | antagonistas do receptor da histamina 3 | |
BRPI0510501A (pt) | antagonistas do receptor 3 de histamina | |
DE602006018301D1 (de) | Histamin-3-rezeptorantagonisten | |
UA88719C2 (ru) | Антагонисты рецепторов гистамина-3 | |
WO2007063385A3 (en) | Spirocyclic amine histamine-3 receptor antagonists | |
WO2007105053A3 (en) | Tetralines antagonists of the h-3 receptor | |
WO2007138431A3 (en) | Azabicyclic ether histamine-3 antagonists | |
WO2007088450A3 (en) | Chromane antagonist of the h-3 receptor | |
BRPI0516079A (pt) | antagonistas de receptor de histamina-3 | |
ME02495B (me) | Tretman poremećaja koji su u vezi sa bdnf primenom lakvinimoda | |
MX2009007782A (es) | Sal de tosilato de un compuesto terapeutico y composiciones farmaceuiticas de la misma. | |
BRPI0514820A (pt) | antagonistas de receptor de histamina-3 amina azabicìclicos | |
BRPI0512567A (pt) | compostos antagonistas de receptor de histamina-3 diazabicìclico e respectivas composições farmacêuticas | |
ATE410163T1 (de) | Verfahren zur behandlung und diagnose von atemstörungen im schlaf mit zonisamid und mittel zur durchführung des verfahrens | |
BRPI0816571A2 (pt) | "composto, processo para preparação do composto, composição farmacêutica, agente e método para o tratamento de uma doença ou uma desordem do sistema nervoso central relacionada à ou afetada pelo recptor 5-ht6" | |
CO5011065A1 (es) | Ligandos del receptor h3, del tipo fenil-alquil-imidazoles | |
EP3194026A1 (en) | Mao-b inhibitors and rehabilitation | |
TH88617A (th) | ฮิสทามีน-3 รีเซพเตอร์ แอนทาโกนิสท์ | |
CY1114789T1 (el) | Ανταγωνιστες υποδοχεα ισταμινης-3 | |
TH88617B (th) | ฮิสทามีน-3 รีเซพเตอร์ แอนทาโกนิสท์ | |
Kushwaha et al. | Role of Melatonin as a Biomarker and Therapeutic agent in modulating the circadian rhythm in Covid-19 | |
Shanmuga Priya | Effect of fentanyl Vs ketamine on the incidence of emergence delirium from sevoflurane anesthesia in pediatric patients undergoing tonsillectomy | |
UA141144U (uk) | Спосіб лікування органічних психічних розладів |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired |